Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells $42,930.84 in Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith Goldan sold 2,082 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $20.62, for a total transaction of $42,930.84. Following the completion of the sale, the chief financial officer directly owned 143,839 shares of the company’s stock, valued at $2,965,960.18. The trade was a 1.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Syndax Pharmaceuticals Trading Up 4.3%

Shares of NASDAQ SNDX opened at $21.01 on Monday. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $22.73. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -5.82 and a beta of 0.46. The company has a quick ratio of 4.42, a current ratio of 4.64 and a debt-to-equity ratio of 2.78. The company’s fifty day moving average is $20.67 and its 200-day moving average is $17.07.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. UBS Group increased their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and issued a $56.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. JPMorgan Chase & Co. lowered their price objective on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Finally, Barclays boosted their price objective on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.20.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in Syndax Pharmaceuticals by 478.8% in the first quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock valued at $4,637,000 after purchasing an additional 312,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Syndax Pharmaceuticals by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after acquiring an additional 3,094 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Syndax Pharmaceuticals by 18.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock worth $2,466,000 after acquiring an additional 30,596 shares in the last quarter. Finally, Aberdeen Group plc boosted its position in Syndax Pharmaceuticals by 129.1% during the second quarter. Aberdeen Group plc now owns 303,426 shares of the company’s stock valued at $2,842,000 after purchasing an additional 170,993 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.